Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Louise A Cooley; Claire Dendle; J Wolf; B W Teh; S C Chen; Craig S Boutlis; Karin A Thursky

doi:10.1111/imj.12599

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Louise A Cooley, Claire Dendle, J Wolf, B W Teh, S C Chen, Craig S Boutlis, Karin A Thursky

School of Clinical Sciences at Monash Health

Research output: Contribution to journal › Article › Research › peer-review

185 Citations (Scopus)

Abstract

Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

Original language	English
Pages (from-to)	1350 - 1363
Number of pages	14
Journal	Internal Medicine Journal
Volume	44
Issue number	12b
DOIs	https://doi.org/10.1111/imj.12599
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.12599

Cite this

@article{d09d7d290a4f4ab7937a9a54ae5e80c3,

title = "Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014",

abstract = "Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.",

author = "Cooley, {Louise A} and Claire Dendle and J Wolf and Teh, {B W} and Chen, {S C} and Boutlis, {Craig S} and Thursky, {Karin A}",

year = "2014",

doi = "10.1111/imj.12599",

language = "English",

volume = "44",

pages = "1350 -- 1363",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "12b",

}

TY - JOUR

T1 - Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

AU - Cooley, Louise A

AU - Dendle, Claire

AU - Wolf, J

AU - Teh, B W

AU - Chen, S C

AU - Boutlis, Craig S

AU - Thursky, Karin A

PY - 2014

Y1 - 2014

N2 - Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

AB - Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

UR - http://onlinelibrary.wiley.com/doi/10.1111/imj.12599/pdf

U2 - 10.1111/imj.12599

DO - 10.1111/imj.12599

M3 - Article

SN - 1444-0903

VL - 44

SP - 1350

EP - 1363

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 12b

ER -

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Abstract

UN SDGs

Access to Document

Other files and links

Cite this